← Leaderboards
John Michael Streicher
University Of Arizona
$5,241,021
Attributed
$5,241,021
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,241,021 · 3
By mechanism
R01$4,811,021 · 2
R21$430,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Side Effect”
- Jeffrey Reich · Sparian Biosciences, Inc.$13,729,307
- Jacob D Estes · Oregon Health & Science University$9,581,486
- James N Campbell · Centrexion Therapeutics Corporation$8,662,635
- Gary Fanger · Rise Therapeutics, Llc$8,225,136
- Katherine Teresa Mills · Tulane University Of Louisiana$7,657,098
- Warren David Lo · Virginia Polytechnic Inst And St Univ$7,249,509
Research focus
Side EffectBrainPharmaceutical PreparationsDoseOpioidRewardsMorphineIn VitroPainTailResponseAffectInvestigationAnalgesicsAddictionSpinal CordOralAcute PainPain ManagementQuality Of LifeChronic PainOverdosePain ModelOpioid Abuse
Grant awards (14)
Development of Hsp90 Isoform- Selective Inhibitors as a Novel Opioid Dose-Reduction Therapy$631,104
R01 · FY2025 · DA · contact PI
Therapeutic and Mechanistic Evaluation of Cannabis sativa Terpenes in Neuropathic Pain$286,922
R01 · FY2025 · AT · contact PI
Development of Hsp90 Isoform- Selective Inhibitors as a Novel Opioid Dose-Reduction Therapy$631,104
R01 · FY2024 · DA · contact PI
Therapeutic and Mechanistic Evaluation of Cannabis sativa Terpenes in Neuropathic Pain$312,962
R01 · FY2024 · AT · contact PI
Development of Hsp90 Isoform- Selective Inhibitors as a Novel Opioid Dose-Reduction Therapy$631,104
R01 · FY2023 · DA · contact PI
Therapeutic and Mechanistic Evaluation of Cannabis sativa Terpenes in Neuropathic Pain$319,856
R01 · FY2023 · AT · contact PI
Development of Hsp90 Isoform- Selective Inhibitors as a Novel Opioid Dose-Reduction Therapy$631,104
R01 · FY2022 · DA · contact PI
Therapeutic and Mechanistic Evaluation of Cannabis sativa Terpenes in Neuropathic Pain$320,324
R01 · FY2022 · AT · contact PI
Development of Hsp90 Isoform- Selective Inhibitors as a Novel Opioid Dose-Reduction Therapy$67,928
R01 · FY2022 · DA · contact PI
Development of Hsp90 Isoform- Selective Inhibitors as a Novel Opioid Dose-Reduction Therapy$657,854
R01 · FY2021 · DA · contact PI
Therapeutic and Mechanistic Evaluation of Cannabis sativa Terpenes in Neuropathic Pain$320,759
R01 · FY2021 · AT · contact PI
Development of a Selective Mu-Delta Opioid Receptor Heterodimer Antagonist Using a Linked Bivalent Pharmacophore Approach$191,875
R21 · FY2019 · DA · contact PI
Development of a Selective Mu-Delta Opioid Receptor Heterodimer Antagonist Using a Linked Bivalent Pharmacophore Approach$7,875
R21 · FY2019 · DA · contact PI
Development of a Selective Mu-Delta Opioid Receptor Heterodimer Antagonist Using a Linked Bivalent Pharmacophore Approach$230,250
R21 · FY2018 · DA · contact PI